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A stability-indicating reversed-phase high performance liquid chromatographic (RP-
HPLC) method has been developed and validated for simultaneous estimation of 
atorvastatin calcium and ezetimibe for their multicomponent dosage form. The proposed 
RP-HPLC method utilizes a 125 mm x 4.6 mm i.d 5 µm Phenomenex C-18 column at 
ambient temperature; the optimum mobile phase consists of acetonitrile and 0.4% v/v 
triethylamine (pH adjusted to 5.5 with ortho-phosphoric acid) in the ratio of 55:45, v/v 
respectively, flow rate of 1.0 ml/min. Measurements were made at a wavelength of 
231 nm. Multicomponent dosage form was exposed to thermal, photolytic, hydrolytic 
and oxidative stress. No co eluting, interfering peaks from excipients, impurities were 
observed for the degradation products and hence the method was found to be specific. 
The method was linear in the range of 5-25 μg/ml for atorvastatin calcium and ezetimibe. 
The mean recoveries were 98.82% and 98.72% for atorvastatin calcium and ezetimibe 
respectively. The method was validated for linearity, range, precision, accuracy, 
specificity, selectivity, intermediate precision, ruggedness, robustness, solution stability 
and suitability.
KEY WORDS: Atorvastatin. Ezetimibe. Degradation. Stress testing. Stability-indicating. 
Validation.
RESUMEN
Se desarrolló y validó un método estable de cromatografía líquida de alta eficacia de fase 
reversa (RP-HPLC) para la estimación simultánea de atorvastatina de calcio y ezetimiba 
en su forma de dosificación multicomponente. El método RP-HPLC propuesto utiliza, a 
temperatura ambiente, una columna C-18 Phenomenex de 125 mm x 4,6 mm y d.i de 5 
µm; la fase móvil óptima consta de acetonitrilo y 0,4% v/v de trietilamina (pH ajustado 
a 5,5 con ácido ortofosfórico) en una proporción de 55:45, v/v, respectivamente, y una 
velocidad de flujo de 1,0 ml/min. Las medidas se realizaron a una longitud de onda de 231 
nm. La forma de dosificación multicomponente se expuso a estrés oxidativo, hidrolítico, 
fotolítico y térmico. No se observaron, en la degradación de productos, ni impurezas 
ni picos de coelución o interferencia por excipientes, y, además, el método resultó ser 
específico. El método fue linear, en el rango de 5-25 μg/ml para atorvastatina de calcio 
y ezetimiba. Las recuperaciones medias fueron del 98,82% y 98,72% para atorvastatina 
de calcio y ezetimiba, respectivamente. El método se validó para linealidad, rango, 
precisión, exactitud, especificidad, selectividad, precisión intermedia, dureza, robustez, 
estabilidad de la disolución e idoneidad.
PALABRAS CLAVE: Atorvastatina. Ezitimiba. Degradación. Prueba de estrés. Indicador 
de estabilidad. Validación
Simultaneous RP-HPLC method for the stress 
degradation studies of atorvastatin calcium and 
ezetimibe in multicomponent dosage form
Rajasekaran A, Sasikumar R, Dharuman J.
Department of Pharmaceutical Analysis; KMCH College of Pharmacy, Coimbatore, India
Correspondence: Dr. 
A.Rajasekaran.M.Pharm, Ph.D.,
KMCH College of Pharmacy,
Kovai Estate, Kalapatti Road, 








12 Ars Pharm. 2011; 52(3): 12-18.
INTRODUCTION
Atorvastatin calcium (ATV) is Chemically [R-(R*, R*)]-
2-(4-fluorophenyl)-[beta], dihydroxy-5-(1-methylethyl)-
3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-
heptanoic acid, calcium salt (2:1) trihydrate1. Ezetimibe 
(EZE) is (3R, 4S)-1-(4-flurophenyl)-3-[(3S)-3- (4-flurophenyl)-
3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone2. 
Atorvastatin is a synthetic lipid-lowering agent that inhibits 
[beta]-hydroxy-[beta]-methylglutaryl-coenzyme A (HMG-
CoA) reductase, and ezetimibe inhibits the absorption of 
cholesterol, decreasing the delivery of intestinal cholesterol 
to the liver. The combined dosage form of ATV and EZE 
has recently been introduced in the market, where the co 
administration of EZE with ATV offers a well-tolerated 
and highly efficient new treatment option for patients with 
dyslipidemia and may help in prescribing a low dose ATV, 
which reduce side effects3. 
Detailed survey of analytical literature of ATV revealed 
several methods viz, LC4,5 and LC/MS6,7 for determination 
in plasma and serum; LC8 for determination in human serum 
and pharmaceutical formulations; LC9,10 for determination 
in pharmaceuticals in combination with other drugs 
and high-performance thin-layer chromatography11 for 
determination in pharmaceuticals. Similarly, a survey of 
the analytical literature for EZE revealed methods based 
on LC12 for determination in pharmaceuticals and LC/
tandem MS13,14 for determination in human plasma and 
serum. A stability-indicating LC method with gradient 
elution has been reported for determination of EZE15. None 
of the reported analytical procedures described a stability-
indicating method for simultaneous determination of ATV 
and EZE in the presence of their degradation products. 
Hence the present study was aimed to establish inherent 
stability of ATV and EZE through stress studies under 
a variety of ICH recommended test conditions and to 
develop a stability-indicating assay method.
MATERIALS AND METHODS
Instruments and Chromatographic Conditions
Shimadzu HPLC with LC-20AT prominence liquid 
chromatogram, Rheodyne 7725i with 20 µl loop injector, 
SPD-M20A Prominence-diode array detector and Sonica 
ultrasonic cleaner sonicator was used. The output signal 
was monitored and processed using lab solution software 
on a HCL computer. Stability studies were carried out in a 
humidity chamber and photo stability studies were carried 
out in a photo stability chamber. Thermal stability studies 
were performed in a dry air oven. The chromatographic 
column used was a phenomenonx C18, 250 x 4.6 mm i.d. 
with 5 mm particles. Mobile phase A contains 0.4% v/v 
triethylamine, pH adjusted to 5.5 using orthophosphoric 
acid. Mobile phase B contains acetonitrile, in the ratio of 
45:55 (v/v). The flow rate of mobile phase was 1.0 ml min-1. 
The column temperature was maintained at 25ºC ± 2ºC and 
the detection was monitored at a wavelength of 231 nm. 
The injection volume was 20 µl.
Drug and chemicals
ATV and EZE were supplied by Micro Labs (Bangalore, 
India) and combined dosage form of ATV and EZE 
was purchased from local pharmacy.  The HPLC grade 
acetonitrile, analytical reagent grade hydrochloric acid, 
sodium hydroxide and hydrogen peroxide were purchased 
from Merck, Germany. HPLC grade water was prepared 
by using Millipore MilliQ plus water purification system. 
Preparation of Stock Solutions
A stock solution of ATZ and EZE standard and sample 
(10 µg/ml) were prepared by dissolving an appropriate 
amount in mobile phase.
Analysis of Dosage Forms
Twenty tablets were weighed, their mean weight was 
determined, and they were crushed in a mortar. An amount 
of powdered mass equivalent to 10 mg each of ATV and 
EZE was weighed and transferred into a conical flask. 
The drugs from the powder were dissolved and extracted 
with 7 ml mobile phase. To ensure complete extraction 
of the drugs, the solution was sonicated for 30 min. The 
extract was filtered through Whatmann filter paper No. 
41 (Gelman Laboratory, Mumbai, India). The extract was 
transferred to a 10 ml volumetric flask, and the volume 
was made up to the line with mobile phase. A 1 ml aliquot 
from this solution was transferred in a 10 ml volumetric 
flask, and the volume was adjusted with mobile phase up 
to the mark (sample stock solution). Aliquot of sample 
stock solution was suitably diluted with mobile phase to 
get final concentration of 10 µg/ml for ATV and EZE. 
Stress Studies
All stress degradation studies were performed at an initial 
drug concentration of 10 µg/ml.
Acid hydrolysis
Twenty five mg of the sample was transferred to a round-
bottomed flask, and then 10 ml of 1.0 M HCl was added 
to the above, and refluxed for 2 h in a boiling water bath. 
At the end of the exposure, the solution was cooled and 
neutralized with 1.0 M NaOH and transferred into a 250 ml 
volumetric flask and the volume was made up with mobile 
phase.
Base hydrolysis
Twenty five mg of the sample was transferred to a round 
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bottomed flask, and then 10 ml of 1.0 M NaOH was added 
to the above, and refluxed for 2 h in a boiling water bath. 
At the end of the exposure the solution was cooled and 
neutralized with 1.0 M HCl and transferred into a 250 ml 
volumetric flask and the volume was made up with mobile 
phase. 
Oxidation
Twenty five mg of the sample was transferred to a round-
bottomed flask for an exposure of 2 h.  Five to 10 ml of 10% 
hydrogen peroxide was added to the above, and refluxed 
for 2 h in a boiling water bath. At the end of the exposure, 
the solution was cooled and transferred into a 250 ml round 
bottomed flask and the volume was made up with mobile 
phase. 
Validation of the method
System suitability
System suitability of method was performed by calculating 
the chromatographic parameters namely, column efficiency, 
resolution peak asymmetry factor and capacity factor on 
the repetitive of injection of standard solution.
Linearity and range
A stock solution of the drug was prepared at strength of 1 
mg/ml. It was diluted to prepare solutions containing 5–25 
µg/ml of the drug. The solutions were injected in triplicate 
into the HPLC column, keeping the injection volume 
constant (20 µl). 
Accuracy 
The accuracy of the method was evaluated in triplicate 
in different concentration levels i.e. 8, 10 and 12 µg/ml in 
bulk samples of ATV and EZE; the percentage of recoveries 
were calculated. 
Precision
The precision of the method was evaluated in terms of 
intermediate precision (intra-day and inter-day). Three 
different concentrations of ATV and EZE were analyzed 
in six independent series during the same day (intra-day 
precision) and six consecutive days (inter-day precision); 
within each series every sample was injected in triplicate. 
The %RSD values of intra- and inter-day studies for ATV 
and EZE showed that the precision of the method was 
satisfactory.
Sensitivity
The sensitivity of the method was determined with respect 
to LOD, LOQ. The LOD was calculated as 3 times the noise 
level and LOQ was calculated as 10 times the noise level. 
Ruggedness and robustness of the method
Method robustness and ruggedness was determined by 
analyzing same sample at normal operating conditions 
and also by changing some operating analytical conditions 
such as column make, mobile phase composition, flow 
rate, instrument and analyst. 
RESULTS AND DISCUSSION
To develop a precise, accurate, specific and suitable 
stability-indicating RP-LC method for the simultaneous 
estimation of ATV and EZE, different mobile phases were 
used and the proposed chromatographic conditions were 
found appropriate for quantitative determination in the 
presence of degradation products and impurities. The 
optimum mobile phase consisted of 0.4% v/v triethylamine 
(pH adjusted to 5.5 with ortho phosphoric acid) and 
acetonitrile; mobile phase flow rate of 1.0 ml min-1; and 
UV detection at 231 nm. This was selected because it was 
found to ideally resolve the peaks of ATV (retention time, 
4.71 min) and EZE (retention time, 8.15 min) and gave 
complete separation of their degradation products and 
impurities and ambient temperature for the column were 
found to be best for analysis.
Linearity and range
Five working solutions for each analyte in the range of 5-25 
µg/ml for ATV and EZE were simultaneously prepared. 
Each solution was injected in five replicates into the HPLC 
column, keeping the injection volume constant (20 µl). 
The linear regressions analysis of ATV and  EZE were 
constructed by plotting the peak area of the analytes (y) 
versus analytes concentration (µg ml−1) in (x) axis. The 
calibration curves were linear in the range of 5-25 µg/m for 
each analyte, with a mean correlation coefficient (r) of more 
than 0.9999 and the mean of regression equations of y = 
34476×C + 21283 and y = 29494×C -12490 for ATV and EZE, 
respectively. The mean values (± S.D. n = 5) of correlation 
coefficient, slope, and intercept were calculated.
Precision
The intraday and interday variation of the method was 
evaluated at 5 different concentration levels (5, 10 and 20 
µg/ml). The % R.S.D. values of within-day and day-to-
day study were <2% for ATV and EZE revealed that the 
proposed method is sufficiently precise.
Ruggedness and robustness of the method
As recommended in the ICH Guidelines and the Dutch 
Pharmacists Guidelines a robustness assessment was 
performed during the development of the analytical 
procedure16. The ruggedness17 of the method is assessed by 
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Table 1: Results of forced degradation studies of ATV and EZE samples using the proposed method
Table 2: System Suitability parameters




Acidic/0.1 M HCl/24 h/Solution/Room temperature 86.11 9.23
Acidic /0.1 M HCl /2 h/Solution/Elevated temperature (70˚C) 87.83 9.53
Base / 0.1 M NaOH/24  h/ Solution/Room temperature 8.32 88.50
Base / 0.1 M NaOH/2 h/ Solution/ Elevated  temperature (70˚C) 8.58 88.69
Oxidative /30% H2O2 /24  h/ Solution/Room temperature 48.1 38.0
Oxidative /30% H2O2 /2  h/ Solution/ Elevated  temperature (70˚C) 49.52 44.33
Dry heat/120˚C/2 h/Solid 7.38 2.74
Photolysis/ UV/2 h /Solid 4.51 5.33
Parameters ATV EZE
Number of theoretical plates/ column efficiency 5174 9304
HETP 32.10 16.34
Tailing factor / Asymmetry factor 1.02 1.08
Capacity factor (k’) 2.759 2.373
Limit of detection LOD (µg/ml) 0.44 0.52
Limit of quantification LOQ (µg/ml) 1.34 1.57
Resolution 3.996 8.234
comparison of the intra-day and inter-day assay results for 
ATV and EZE that has been performed by two analysts. 
The %RSD values for intra-day and inter-day assays of 
ATV and EZE in the commercial tablet (Encoded as AE-01) 
performed in the same laboratory by two analysts did not 
exceed 0.2% and 0.25% respectively, indicating the method 
is rugged. 
In addition, the robustness of the method was investigated 
under a variety of conditions including changes of pH 
of the eluent, flow rate and of buffer composition18. The 
degree of reproducibility of the results obtained as a result 
of small deliberate variations in the method parameters 
and by changing analytical operators has proven that the 
method is robust.
System suitability
System suitability of method was performed by calculating 
the chromatographic parameters namely; column efficiency, 
resolution peak asymmetry factor and capacity factor on 
the repetitive of injection of standard solution were shown 
in table 2.
Accuracy
Accuracy of the method was checked by a recovery 
study using the standard addition method at 3 different 
concentration levels, i.e., a multilevel recovery study. The 
preanalyzed samples were spiked with an extra 80, 100, 
and 120% of the standard ATV and EZE, and the mixtures 
were analyzed by the proposed method. Results of the 








Amount of standard 
recovered (µg/ml) Recovery (%) %RSD
ATV
I 8 10 7.99 99.94 0.0650
II 10 10 9.96 99.66 0.2172
III 12 10 11.97 99.81 0.1585
AZE
I 8 10 7.98 99.81 0.1128
II 10 10 10.32 100.31 0.3018
III 12 10 11.83 98.60 1.5420
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Table 4: Assay of ATV and EZE tablet dosage forms by RP-HPLC Method
Assay of ATV and EZE from Its Tablet Dosage Forms
The assay results of ATV and EZE in tablet dosage forms 
were comparable with the value claimed on the label. The 
assay results obtained indicated that the method is suitable 
for the routine analysis of ATV and EZE in their combined 
dosage forms (table 4).
Forced degradation studies
The chromatogram of samples degraded with acid, base 
and hydrogen peroxide showed well separated peaks of 
pure ATV and EZE as well as some additional peaks at 
different Rt values. The spots of degraded product were 
resolved from the drug peak. The chromatograms are 
shown in figures 1,2,3,4,5 and 6. The number of degradation 
product with their Rt values listed in table 1.
Formulation
Labeled amount, (mg) Amount found, (mg) % Assay %RSD
ATV EZE ATV EZE ATV EZE ATV EZE
AE-01 10 10 9.88* 9.82* 98.88* 98.82* 0.321 0.312
*average of 5 determinations
CONCLUSION
Based on the peak purity study results by the proposed 
method, it can be concluded that there is no other co 
eluting peak with the main peaks and hence the method is 
specific for the estimation of ATV and EZE in the presence 
of degradation products. Although no attempt was made 
to identify the degradation products, the described method 
can be used as stability indicating method for the assay 
of ATV and EZE in their combined dosage forms.  The 
gradient simultaneous RP-HPLC method proved to be 
simple, linear, precise, accurate and specific. The method 
was completely validated showing satisfactory data for all 
the method validation parameters that were tested. As the 
described method is capable of separating the drug from 
its degradation products, it can be employed as a stability 
Figure 1: Chromatogram 
of ATV and EZE standard 
solution (10 µg/ml)
Figure 2: Chromatogram 
of combined formulation 
treated with 0.1 M HCl 
at elevated temperature 
(70˚C) for 2 h.
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Figure 3: Chromatogram 
of combined formulation 
treated with 0.1 M NaOH 
at elevated temperature 
(70˚C) for 2 h
Figure 4: Chromatogram 
of combined formulation 
treated with 30% H2O2 
at elevated temperature 
(70˚C) for 2 h
Figure 5: Chromatogram 
of combined formulation 
after dry heat (120˚C) 
degradation for 2 h
Figure 6: Chromatogram of 
combined formulation after 
photolytic degradation for 2 h
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